Artificial Intelligence for Healthy Longevity
147,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
  • Broschiertes Buch

This book reviews the state-of-the-art efforts to apply machine learning and AI methods for healthy aging and longevity research, diagnosis, and therapy development. The book examines the methods of machine learning and their application in the analysis of big medical data, medical images, the creation of algorithms for assessing biological age, and effectiveness of geroprotective medications.
The promises and challenges of using AI to help achieve healthy longevity for the population are manifold. This volume, written by world-leading experts working at the intersection of AI and aging,…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
This book reviews the state-of-the-art efforts to apply machine learning and AI methods for healthy aging and longevity research, diagnosis, and therapy development. The book examines the methods of machine learning and their application in the analysis of big medical data, medical images, the creation of algorithms for assessing biological age, and effectiveness of geroprotective medications.

The promises and challenges of using AI to help achieve healthy longevity for the population are manifold. This volume, written by world-leading experts working at the intersection of AI and aging, provides a unique synergy of these two highly prominent fields and aims to create a balanced and comprehensive overview of the application methodology that can help achieve healthy longevity for the population.
The book is accessible and valuable for specialists in AI and longevity research, as well as a wide readership, including gerontologists, geriatricians, medical specialists,and students from diverse fields, basic scientists, public and private research entities, and policy makers interested in potential intervention in degenerative aging processes using advanced computational tools.

Autorenporträt
Alexey Moskalev, PhD, is a Corresponding Member of the Russian Academy of Sciences, Doctor of Biology, the Director of the Institute of Biogerontology of Lobachevsky State University. He is a faculty member of the School of Systems Biology, George Mason University, USA. He has authored more than 100 publications in the fields of genetics of aging, longevity and radiation genetics. His research has revealed the geroprotective and synergistic effects of different inhibitors of PI3K, TOR, NF-kB, as well as identified the geroprotective effects of fucoxanthin and ibuprofen. He has contributed to the work that uncovered the mechanisms of exceptional longevity of Myotis brandtii bats and grey whale mammalian species. Having been actively involved in the Digital Ageing Atlas, Geroprotectors and DrugAge international collaborations, his research has helped build the datasets on biomarkers of aging and anti-aging drugs. He is the recipient of the 2021 Russian Research Excellence Awardin Life Sciences. Ilia Stambler, PhD, is the Chairman and Chief Science Officer of "Vetek" (Seniority) Association - the Movement for Longevity and Quality of Life, Israel, and a researcher at the Department of Science, Technology and Society, Bar Ilan University, Israel. His research has focused on the historical and social implications of aging and life extension research and mathematical modeling of aging and aging-related diseases. He is actively involved in advocacy for aging and longevity research, serving as an executive committee member of the International Society on Aging and Disease and International Longevity Alliance, trustee and director of the Biogerontology Research Foundation, fellow and policy director at the Global Healthspan Policy Institute. He has published over 60 academic journal articles and book chapters and has authored two books on aging and longevity. He was an active player in the campaign for the inclusion of aging into the 2017 WHO work program, and for establishing the section on "research, development and education for healthy longevity" in the Israel National Masterplan on Aging in 2019. Alex Zhavoronkov, PhD, is the founder and CEO of Insilico Medicine, a leader in next-generation generative artificial intelligence technologies for drug discovery and biomarker development. Under his leadership, Insilico raised over $400 million in multiple rounds from expert investors, opened R&D centers in six countries or regions, and partnered with multiple pharmaceutical, biotechnology, and academic institutions, nominated 11 preclinical candidates, and entered human clinical trials with AI-discovered novel target and AI-designed novel molecule. Since 2015 he has invented critical technologies in the field of generative artificial intelligence and reinforcement learning (RL) for generation of novel molecular structures with the desired properties and generation of synthetic biological and patient data. Since 2012 hepublished over 160 peer-reviewed research papers and two books. He founded and co-chairs the Annual Aging Research, Drug Discovery and AI Forum (9th annual in 2022), the world's largest event on aging in the pharmaceutical industry. He is the adjunct professor of artificial intelligence at the Buck Institute for Research on Aging.